Albert Cha
QuietNamed in filings at Vivo Innovation
- Board seats filed
- 8
all filings on record
Named in filings at Vivo Innovation
all filings on record
last 24 months
from a verified or cited source
| Menlo Therapeutics | Biotech & pharma | July 2017 | Venbio Global Strategic |
| Ascendis Pharma A/S | Biotech & pharma | November 2014 | Caduceus Capital, Capra CLO Founders, Orbimed Asia Partners, Orbimed Genesis, Sofinnova Venture Partners |
| MINERVA SURGICAL | Medical devices | September 2014 | Versant Affiliates, Versant Venture Capital |
| Carbylan Therapeutics | Biotech & pharma | September 2014 | None on file |
| Aclaris Therapeutics | Biotech & pharma | September 2014 | Aisling Capital, Sofinnova Venture Partners |
| ProNAi Therapeutics | Biotech & pharma | April 2014 | Orbimed Asia Partners, Orbimed Genesis |
| TRIA Beauty | Medical devices | November 2013 | Aisling Capital |
| AIRXPANDERS | Medical devices | January 2012 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Albert Cha on the board, based on 8 filed seats with a verified or cited source.